Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

beta Amyloid 16 (AA 1-16) Peptid

Wirt: Synthetic Without preservative
Rockland
Produktnummer ABIN6699436
Hersteller Produkt- Nr.: 000-001-l00

Kurzübersicht für beta Amyloid 16 (AA 1-16) Peptid (ABIN6699436)

Target

beta Amyloid 16

Quelle

Synthetic
  • Protein Region

    AA 1-16

    Hersteller Produkt- Nr.

    000-001-l00

    Hersteller

    Rockland

    Verwendungszweck

    Beta Amyloid 1-16 Peptide

    Reinheit

    Greater than 95% specific peptide.
  • Applikationshinweise

    Other: Control peptide should be used at 1.0 μg per 1.0 μL of antiserum per assay.

    Application_Note: Beta Amyloid 1-16 Control Peptide is suitable for use in ELISA, Western Blot, Dot blot, PCA, and other assays. Control peptide should be used at 1.0 μg per 1.0 μL of antiserum in per assay. Specific conditions for reactivity should be optimized by the end user.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    Reconstitution_Buffer: Restore with deionized water (or equivalent)

    Reconstitution_Volume: 1.0 mL

    Konzentration

    1.0 mg/mL

    Konservierungsmittel

    Without preservative

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Store vial at 2 - 8 ° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to immediate use.

    Haltbarkeit

    12 months
  • Target

    beta Amyloid 16

    Hintergrund

    Synonyms: ABPP, APP1, Alzheimer disease amyloid protein, Cerebral vascular amyloid peptide, Protease nexin-II, control peptide, blocking peptide

    Background: Amyloid peptides, derived from amyloid precursor protein (APP), are thought to play a role in the development of the senile plaques associated with Alzheimer's disease. The amyloid hypothesis presupposes that flaws in the processing of APP result in abnormally high levels of the longer, ""stickier"" forms of beta amyloid, known as Aβ42 and Aβ43, leading to aggregation of amyloid in the neuronal cell death and ultimately neuronal death. Mutations in the structure of Aβ40 and related peptides as well as in some of the enzymes involved in the processing of APP have been shown to alter the processing of APP. The sporadic (i.e., non-genetic) form of the disease, however, is far more common, caused by aging in concert with a number of both genetic and environmental risk factors.

Sie sind hier:
Chat with us!